Previous 10 | Next 10 |
Esperion ([[ESPR]] +3.6%) announces pooled data from four of Phase 3 studies evaluating Nexletol (bempedoic acid) as an adjunct to diet for lowering LDL-C ("bad" cholesterol) in adults.Data analysis from a subgroup of 580+ patients who cannot tolerate any dose of a statin, show...
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 - - Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and...
Esperion (ESPR) has priced upsized $250M (from $200M) of 4.00% convertible senior unsecured subordinated notes due November 15, 2025 in a private offering.nitial purchasers granted an option to purchase up to an additional $30M of the notes.Closing date is November 16. Interest on the no...
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qu...
Esperion ([[ESPR]] -9.2%) to offer $200M convertible senior subordinated notes due 2025 to institutional buyers. Initial purchasers have an option to purchase up to an additional $30M notes.Conversion price and other terms are yet to be determined.Net proceeds will be used to pay the cos...
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Subordinated Notes due 2025 (the “notes”) in a pr...
Esperion's approved product bempedoic acid is a non-statin, lipid-lowering drug with proven efficacy. However, high burn rate, poor uptake, and coronavirus have all dampened the prospects of the company. The latest earnings call has a lot of aggressive posturing, but does not give...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Esperion Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation
Gainers: Alaska Communications Systems (ALSK) +58%.Beasley Broadcast (BBGI) +39%.JAKKS Pacific (JAKK) +29%.BioLineRx (BLRX) +27%.Gannett Co (GCI) +25%.Inspire Medical Systems (INSP) +24%.GW Pharmaceuticals (GWPH) +20%.Collectors Universe (CLCT) +20%.Telenav (TNAV) +20%.Aptevo Therap...
Gainers: Inspire Medical Systems (INSP) +24%, GW Pharmaceuticals (GWPH) +15%, Aptevo Therapeutics (APVO) +14%, Galera Therapeutics (GRTX) +11%, DBV Technologies (DBVT) +10%.Losers: Esperion Therapeutics (ESPR) -15%, Aurinia Pharmaceuticals (AUPH)...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...